1. Home
  2. NTLA vs AMAL Comparison

NTLA vs AMAL Comparison

Compare NTLA & AMAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • AMAL
  • Stock Information
  • Founded
  • NTLA 2014
  • AMAL 1923
  • Country
  • NTLA United States
  • AMAL United States
  • Employees
  • NTLA N/A
  • AMAL N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • AMAL Commercial Banks
  • Sector
  • NTLA Health Care
  • AMAL Finance
  • Exchange
  • NTLA Nasdaq
  • AMAL Nasdaq
  • Market Cap
  • NTLA 1.0B
  • AMAL 978.7M
  • IPO Year
  • NTLA 2016
  • AMAL 2018
  • Fundamental
  • Price
  • NTLA $9.62
  • AMAL $29.04
  • Analyst Decision
  • NTLA Buy
  • AMAL Buy
  • Analyst Count
  • NTLA 18
  • AMAL 4
  • Target Price
  • NTLA $39.44
  • AMAL $36.13
  • AVG Volume (30 Days)
  • NTLA 3.8M
  • AMAL 311.9K
  • Earning Date
  • NTLA 05-08-2025
  • AMAL 04-24-2025
  • Dividend Yield
  • NTLA N/A
  • AMAL 1.91%
  • EPS Growth
  • NTLA N/A
  • AMAL 20.28
  • EPS
  • NTLA N/A
  • AMAL 3.44
  • Revenue
  • NTLA $57,877,000.00
  • AMAL $304,261,000.00
  • Revenue This Year
  • NTLA N/A
  • AMAL $12.20
  • Revenue Next Year
  • NTLA N/A
  • AMAL $13.99
  • P/E Ratio
  • NTLA N/A
  • AMAL $8.53
  • Revenue Growth
  • NTLA 59.55
  • AMAL 10.81
  • 52 Week Low
  • NTLA $8.30
  • AMAL $21.33
  • 52 Week High
  • NTLA $28.88
  • AMAL $38.19
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 44.22
  • AMAL 29.95
  • Support Level
  • NTLA $8.64
  • AMAL $27.97
  • Resistance Level
  • NTLA $10.68
  • AMAL $31.60
  • Average True Range (ATR)
  • NTLA 0.91
  • AMAL 1.33
  • MACD
  • NTLA -0.09
  • AMAL -0.39
  • Stochastic Oscillator
  • NTLA 30.48
  • AMAL 15.60

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers a range of products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.

Share on Social Networks: